← Back to Search

[18F]-FTC-146 Imaging for Healthy Controls (rSIG Trial)

Phase 1
Waitlist Available
Led By Carolyn Rodriguez, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Capacity to provide informed consent
Ages 18-65
Must not have
Major medical or neurological problem
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights
No Placebo-Only Group

Summary

This trial tests how well a new brain imaging agent works in healthy people.

Who is the study for?
This trial is for healthy individuals aged 18-65, capable of giving informed consent. Participants can be of any gender or ethnicity but must use effective birth control if female. Those with a history of psychiatric diagnoses, major medical or neurological issues, metal implants not suitable for MRI scans, or who are pregnant/nursing cannot join.
What is being tested?
[18F]-FTC-146's reliability in brain uptake is being tested in this study. The goal is to understand how consistently the substance accumulates in the brains of healthy people without influencing factors like medication or existing health conditions.
What are the potential side effects?
Since [18F]-FTC-146 is used as a diagnostic tool and participants are healthy controls, significant side effects are not anticipated. However, typical risks associated with PET imaging may include discomfort at the injection site and exposure to low levels of radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand and can agree to the study's procedures and risks.
Select...
I am between 18 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a serious health or brain condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reliability under test retest conditions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]-FTC-146Experimental Treatment1 Intervention
\[18F\]-FTC-146
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[18F]-FTC-146
2016
Completed Early Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,472 Previous Clinical Trials
17,501,812 Total Patients Enrolled
Carolyn Rodriguez, MD, PhDPrincipal InvestigatorStanford University
6 Previous Clinical Trials
307 Total Patients Enrolled

Media Library

[18F]-FTC-146 Clinical Trial Eligibility Overview. Trial Name: NCT03649555 — Phase 1
Healthy Controls Research Study Groups: [18F]-FTC-146
Healthy Controls Clinical Trial 2023: [18F]-FTC-146 Highlights & Side Effects. Trial Name: NCT03649555 — Phase 1
[18F]-FTC-146 2023 Treatment Timeline for Medical Study. Trial Name: NCT03649555 — Phase 1
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top